Axsome to Submit NDA for AXS-05 in Alzheimer Agitation Following Positive Phase 3 Trials

Published Date: 09 Jan 2025

The ACCORD-2 trial demonstrated a significant reduction in overall worsening compared to placebo, while the ADVANCE-2 trial showed numerically greater improvements without reaching statistical significance.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

2.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

3.

Early detection of breast cancer may be possible with AI-based mammography microcalcification detection and classification.

4.

Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.

5.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot